Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Veracyte Inc VCYT

Healthcare Biotechnology
Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and assure patients. The Company offers tests for thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), interstitial lung diseases (Envisia), and bladder cancer (Decipher Bladder). Its Percepta Nasal Swab test is being run in its Clinical Laboratory... see more

Recent & Breaking News (NDAQ:VCYT)

Veracyte Announces Multiple Decipher Urologic Testing Abstracts to be Presented at the 2023 ASCO Genitourinary (GU) Cancers Symposium

Business Wire February 1, 2023

Veracyte Announces New Data Suggesting Afirma Testing Can Help Personalize Care for Patients with Thyroid Nodules

Business Wire February 1, 2023

Exagen Inc. Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of Directors

GlobeNewswire January 23, 2023

Data Published in JCEM Demonstrate Strong Real-World Performance of Veracyte's Afirma GSC in Thyroid Cancer Diagnosis

Business Wire December 15, 2022

Veracyte Announces Third Quarter 2022 Financial Results

Business Wire November 2, 2022

Veracyte Announces Three Abstracts to Be Presented at SITC 2022 Annual Meeting

Business Wire November 1, 2022

Veracyte to Participate in the Credit Suisse 31st Annual Healthcare Conference

Business Wire October 27, 2022

New Data Suggest Decipher GRID-Derived Genomic Signature Can Help Identify Men with Prostate Cancer Who Should Receive High-Dose Radiotherapy

Business Wire October 25, 2022

Veracyte Data Presented at ATA Annual Meeting Provide New Insights into Molecular Underpinnings of Thyroid Cancer

Business Wire October 24, 2022

New Data Presented at CHEST 2022 Reinforce Clinical Value of Veracyte's Genomic Tests in Interstitial Lung Disease and Lung Cancer

Business Wire October 18, 2022

Veracyte to Release Third Quarter 2022 Financial Results on November 2, 2022

Business Wire October 13, 2022

New Data Published in JNCI Demonstrate Veracyte's Decipher Prostate Genomic Classifier May Improve Identification of Aggressive Prostate Cancer in African American Men

Business Wire September 22, 2022

Veracyte Names John Leite, Ph.D., as General Manager of Pulmonology & Market Access

Business Wire September 13, 2022

New Data Presented at ESMO 2022 Show Veracyte's Decipher Prostate Genomic Classifier May Help Inform Personalized Treatment Decisions in Men with Advanced Prostate Cancer

Business Wire September 11, 2022

New Data Suggest Veracyte's Envisia Genomic Classifier Can Help Predict Disease Progression in Interstitial Lung Disease Patients Treated with Combination Immunosuppressive Therapy

Business Wire September 7, 2022

Veracyte to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

Business Wire September 1, 2022

Veracyte Announces Seven Abstracts to Be Presented at ESMO Congress 2022

Business Wire August 31, 2022

New Data in Nature Medicine Suggest Pre-Treatment Tumor Microenvironment Can Impact Response for CAR T-Cell Therapy in Patients with Large B-Cell Lymphoma

Business Wire August 29, 2022

Veracyte Appoints Eliav Barr, M.D., to Its Board of Directors

Business Wire August 11, 2022

Veracyte Announces Second Quarter 2022 Financial Results

Business Wire August 2, 2022